Prospects and Challenges in the Development of a Norovirus Vaccine

Cortés-Penfield, Nicolás W; Ramani, Sasirekha; Estes, Mary K.; Atmar, Robert L.

doi:10.1016/j.clinthera.2017.07.002

Cited by 99 publications

(67 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NoVs have also been detected in several other species, such as GII in humans and pigs, GIII in cattle, GIV in humans, cats and dogs, GV in mice, GVI and GVII in dogs . Each genogroup of NoV is subdivided further into several genotypes, for examples GI, GII, GIII, GIV, GV, GVI, and GVII, are comprised of 9, 22, 3, 2, 2, 2, and 1 genotypes, respectively …”

Section: Classification and Genome Organizationmentioning

confidence: 99%

“…In addition, NoV‐associated deaths in older adults in upper‐middle and high income countries have also been reported ranging from 2000 to 13 000 deaths per year . Currently, no NoV vaccine is available, however, several vaccine candidates are in development . In this review, we focus on the epidemiology and distribution of NoV and SaV genotypes in Thailand during the period of 2000‐2016.…”

Section: Introductionmentioning

confidence: 99%

“…20 Each genogroup of NoV is subdivided further into several genotypes, for examples GI, GII, GIII, GIV, GV, GVI, and GVII, are comprised of 9, 22, 3, 2, 2, 2, and 1 genotypes, respectively. 17,20 NoV is a small nonenveloped virus of 27-37 nm in diameter. 21 The NoV genome is a linear positive sense, single stranded RNA of approximately 7.6 kb in length.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Molecular epidemiology and genotype distributions of noroviruses and sapoviruses in Thailand 2000‐2016: A review

Khamrin

Maneekarn

2018

Journal of Medical Virology

View full text Add to dashboard Cite

Norovirus (NoV) and sapovirus (SaV) infections remain public health problems in Thailand, particularly, causing an acute gastroenteritis in people of all age groups. This review summarizes the epidemiology and genotype distribution of NoV and SaV in Thailand during the period of 2000-2016. The overall prevalence of NoV infection in patients with acute gastroenteritis of all age groups ranged from 0.09% to 44.7% while those of SaV were 0.0-15.0%. The majority of NoV genogroup detected was NoV GII with a small proportion of NoV GI. The NoV GII.4 was the most predominant genotype (63.4%) followed by GII.3 (15.0%), GII.6 (3.9%), GII.17 (3.3%), GII.13 (2.1%) and many other genotypes with small proportion. Furthermore, eight GII.4 variant strains and 11 different NoV recombinant strains had also been reported. For SaV, 10 different human SaV genotypes were detected including GI.1, GI.2, GI.4, GI.5, GII.1, GII.2, GII.3, GII.4, GIV.1, and GV.1.

show abstract

Section: Classification and Genome Organizationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular epidemiology and genotype distributions of noroviruses and sapoviruses in Thailand 2000‐2016: A review

Khamrin

Maneekarn

2018

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Current vaccine approaches consider GII.4 as a main NoV vaccine antigen (9,29), and therefore it is of interest to determine the level of GII.4 VLP-induced cross-reactive responses to GII.17. no.…”

Section: Introductionmentioning

confidence: 99%

Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera

et al. 2018

View full text Add to dashboard Cite

Majority of norovirus (NoV) outbreaks and sporadic infections in the past 20 years have been caused by GII.4 variants. In 2014, norovirus GII.17 genotype replaced GII.4 strains in several Asian countries and major outbreaks were reported in other continents. As GII.17 is a recently evolved NoV strain, there is a gap especially in immunogenicity data. In the present study we investigated GII.17 virus-like particle (VLP) binding to various cellular ligands, histo-blood group antigens (HBGAs), using human saliva, pig gastric mucin, and synthetic oligosaccharides as HBGA sources. The level of GII.17 immunological cross-reactivity was determined in mice immunized with different monovalent and multivalent NoV VLP compositions. Furthermore, healthy adult volunteers with natural NoV exposure history were analyzed for GII.17-specific seroresponses. The results showed that GII.17 Kawasaki VLPs bind to a wide range of HBGAs, even though fewer than GII.4 VLPs. Immunization of mice with a multivalent VLP formulation containing different genogroup II NoV VLPs was required to obtain the highest magnitude of cross-reactive binding antibodies to GII.17. However, co-immunization with different VLP genotypes did not improve potentially neutralizing antibodies to GII.17, which remained very moderate. Low pre-existing cross-reactive antibodies to GII.17 observed in human adults indicates the presence of a large pool of susceptible individuals in this population. These data suggest that GII.17 and alike newly emerging, distinct NoV genotypes should be considered as an antigenic component for vaccine formulations, which currently widely rely on GII.4-specific immunity.

show abstract

“…have not yet been created (Cortes-Penfield et al, 2017;Duizer et al, 2004 an E. coli-produced P particle vaccine (Cortes-Penfield et al, 2017;Ballard et al, 2015).…”

Section: Other Vaccinesmentioning

confidence: 99%

Rotavirus detection and typing in the rotavirus vaccine era

Ye¹

View full text Add to dashboard Cite

Diarrhoeal disease is a leading cause of morbidity and mortality worldwide. Rotaviruses are the most common cause of severe childhood diarrhoea globally. In Australia, before rotavirus vaccination, rotaviruses caused approximately 10,000 hospitalisations, 22,000 emergency department visits, and 115,000 general practice consultations annually in children aged less than 5 years. On 1 July 2007 Australia became one of the first countries to include rotavirus vaccine into their national immunisation programme. Rotarix was

show abstract

Prospects and Challenges in the Development of a Norovirus Vaccine

Cited by 99 publications

References 71 publications

Molecular epidemiology and genotype distributions of noroviruses and sapoviruses in Thailand 2000‐2016: A review

Molecular epidemiology and genotype distributions of noroviruses and sapoviruses in Thailand 2000‐2016: A review

Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera

Rotavirus detection and typing in the rotavirus vaccine era

Contact Info

Product

Resources

About